AN2 Therapeutics
favorable trial results from phase showed the concentration in lung macrophages site of infection was higher than in plasma am results suggest therapeutically relevant doses of may be achieved in macrophages at doses that are substantially lower than in previous trials an therapeutics | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
19 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
favorable results from phase trial showed the concentration in lung macrophages site of infection was higher than in plasma pois am | AN2 Therapeutics
Related slides by other companies
BioAtla
Investor Presentation
August 2023
encouraging phase results with | BioAtla
ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
BioAtla
Investor Presentation
August 2022
encouraging phase results with | BioAtla
BioAtla
Investor Presentation
August 2022
phase results in stage refractory melanoma phase phase | BioAtla
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io